“Growing Shift Toward Direct Oral Anticoagulants (DOACs) and Personalized Regimens”
- A prominent trend in the Asia-Pacific anticoagulation therapy market is the increasing preference for direct oral anticoagulants over traditional therapies like warfarin due to their predictable pharmacokinetics and reduced need for monitoring.
- Treatment guidelines are now integrating pharmacogenomics and patient-specific risk factors to personalize anticoagulant therapy, especially in complex comorbid populations.
- For example, DOACs such as apixaban and rivaroxaban have gained widespread adoption across Japan, China, and Australia for stroke prevention in atrial fibrillation.
- Technological innovations such as point-of-care INR testing and mobile health platforms are improving therapeutic adherence and outcome monitoring.
- Rising burden of lifestyle diseases, aging populations, and sedentary behavior across urban centers are contributing to growing demand for chronic anticoagulation therapy.
